Search
Now showing items 1-9 of 9
Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers
(ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)
Background: The standard therapy for stage I rectum cancer is surgical resection. Currently, there is no strong evidence to suggest that any type of adjuvant therapy is beneficial. The risks of local relapse and distant ...
The diagnostic and prognostic value of UHRF-1 and p53 in gastric cancer.
(AMER SOC CLINICAL ONCOLOGY, 2014)
…
Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?
(AMER SOC CLINICAL ONCOLOGY, 2014)
…
Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience
(ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)
Background: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at ...
Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients.
(AMER SOC CLINICAL ONCOLOGY, 2014)
…
Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells
(ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)
Background: Breast cancer evolution and tumor progression are controlled by complex interactions between steroid receptors and growth factor receptor signaling. Aberrant growth factor receptor signaling can augment or ...
Oxaliplatin and ototoxicity: is it really safe for hearing?
(TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY, 2014)
Background/aim: Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. ...
Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults
(ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)
Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma ...
